HIROTSU Bioscience Co., Ltd.
A conversation between Mr. Jun Ikeido and our company representative Hirotsu talks about the future that will be opened by “N-NOSE”, the intersection of science and challenge.
Published on our website from today, Bungeishunju July 2024 issue ……
HIROTSU Bioscience Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, Representative: Takasuke Hirotsu, hereinafter referred to as the “Company”) is a joint venture between author Jun Ikeido, author of the novels “Shitamachi Rocket” and the “Naoki Hanzawa” series, and the Company. A conversation with Representative Director Takasuke Hirotsu has been published on our website. The content of the conversation is provided by our company and published in the July 2024 issue of Bungeishunju, which is on sale today.
[Image: https://prtimes.jp/i/90131/90/resize/d90131-90-b3baab54629fb4663f21-0.jpg&s3=90131-90-61c5d53f3da62896836b7162534a99bd-3900×2600.jpg] In the conversation, Mr. Ikeido, who often mentions science and technology originating in Japan in his own books, and Hirotsu, who is also a developer and researcher of “N-NOSE”, talked about the topic of nematode, which has attracted attention and has been taken by over 600,000 people. Many thought-provoking conversations take place, ranging from the innovation and social impact of the cancer test “N-NOSE.”
Mr. Ikeido said, “What Mr. Hirotsu was able to accomplish is extremely impressive given that there are not many examples of university-originated technology being put into practical use. N-NOSE is especially useful for early detection of cancers that are difficult to detect. “It has great potential and will make a significant contribution to society.”
In addition, during the conversation, Dr. Ikeido said, “It is important that young people have access to cancer testing easily,” adding, “Nematode cancer testing is extremely useful for people who are busy with work and childcare.” ” he emphasized. At the end of the conversation, he expressed his hopes for the spread of the technology, saying, “I want him to become the Elon Musk of the cancer testing industry.”
The content of the conversation is available on our website, as well as in the July 2024 issue of Bungeishunju, released today, and on Bungeishunju Online. Please take a look.
Discussion page: https://hbio.jp/news/2024/06/20240610/
About HIROTSU Bioscience
We aim to “protect people’s health and future security” through the research, development, and practical application of unique testing technologies that utilize the abilities of living organisms. Established in 2016, N-NOSE has been put into practical use thanks to the rich ideas and tireless efforts of researchers. In the age of 100-year lifespans, extending healthy life expectancy is important, but it is said that one in two people will develop cancer. We will contribute to solving these social issues with the world’s first groundbreaking technology that utilizes the superior olfactory power of nematodes, which surpasses artificial devices.
Company name HIROTSU Bioscience Co., Ltd.
Address: New Otani Garden Court, 4-1 Kioicho, Chiyoda-ku, Tokyo Representative name: Representative director: Takasuke Hirotsu Date of establishment: August 2016
Main business activities: Research, development, and sales of cancer tests using nematodes and nematode olfactory sensors
Corporate site https://hbio.jp/
About “N-NOSE”
A cancer risk test that uses C. elegans, a nematode with an excellent sense of smell, to accurately detect cancer-specific odors in human urine. By simply submitting urine, it is possible to investigate early cancer risk in a simple, inexpensive, highly accurate, and
comprehensive manner throughout the body.
Service site: https://lp.n-nose.com/
About “N-NOSE plus”
N-NOSE’s next-generation “cancer type identification test”. We use a “special nematode” created by genetically engineering the nematode C. elegans, which responds specifically to the smell of a specific cancer type. This “special nematode” has a high ability to distinguish between specific cancer types and other cancers, making it possible to determine the risk of each cancer type using a non-invasive method. . We are currently treating pancreatic cancer and liver cancer. Service site: https://lp.n-nose.com/
About “N-NOSE Animal”
Cancer tests for dogs, “N-NOSE Dog” and cancer tests for cats, “N-NOSE Neko-chan” were developed using N-NOSE’s technology. Until now, there has not been a cancer test that can be easily taken by dogs and cats that do not show any symptoms, but this test can check the risk of multiple cancers by simply submitting urine, just like in humans. I can. Service provision will begin in 2023.
Service site: https://lp.n-nose.com/animal/
More details about this release:
https://prtimes.jp/main/html/rd/p/000000090.000090131.html